Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Lamont

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Pageof 11